As medicine has transformed HIV from a fatal diagnosis into a manageable chronic condition, a quieter reckoning has emerged: longevity does not guarantee metabolic safety. Researchers at UC San Francisco have found that people whose HIV is fully suppressed by modern treatment still carry hidden scarring in their fat tissue — scarring that predisposes them to type 2 diabetes regardless of their body weight or the medications they take. The discovery reminds us that what is invisible to the eye, and even to the scale, may still be written in the body's deeper language.
Hidden fat scarring linked to diabetes risk in HIV patients despite viral control
The damage is invisible from the outside.
Mark
Why does HIV keep causing diabetes problems even when the virus itself is controlled?
Mimi
The virus isn't the only thing damaging the body. Even when antiretroviral drugs suppress HIV to undetectable levels, the fat tissue underneath the skin develops scarring—fibrosis. That scarring interferes with how insulin works, and that's what drives diabetes risk.
Mark
But if someone with HIV looks healthy and maintains a normal weight, wouldn't their doctor assume they're metabolically fine?
Mimi
That's exactly the problem this research exposes. You can be thin and still have scarred fat tissue. The damage is invisible from the outside. A blood test for endotrophin could change that.
Mark
Is this scarring unique to HIV, or is it the same thing that happens in obesity?
Mimi
It's different. The genes involved are different. In obesity, the body's fat tissue remodels in one way. In HIV, even in thin people, the remodeling follows a different pattern—more immune activation, more structural breakdown.
Mark
Can doctors treat the scarring itself, or just manage the diabetes that results?
Mimi
That's what they're working toward. Right now they can detect it. The next phase is figuring out whether you can reverse it or prevent it from worsening.
Mark
How many people with HIV does this actually affect?
Mimi
We don't know the exact number yet. But as HIV becomes a long-term manageable disease, more people are living long enough to develop these metabolic complications. It's becoming a bigger part of their health picture.
Der Puls
- People living with well-controlled HIV face a diabetes risk that their healthy weight and suppressed viral load do nothing to reveal, exposing a dangerous blind spot in routine care.
- Fat tissue biopsies from 46 HIV patients showed fibrosis — structural scarring — tightly coupled to insulin resistance, a finding that held regardless of body weight or drug regimen.
- A blood protein called endotrophin tracks this hidden scarring and could become a clinical tool to flag the highest-risk patients before diabetes takes hold.
- Gene analysis revealed that HIV-related fat fibrosis carries a molecular fingerprint distinct from obesity-related scarring, suggesting a disease-specific mechanism demanding its own therapeutic approach.
- Researchers caution that causality is not yet proven — the study measured participants at a single point in time — but the findings lay a foundation for intervention trials targeting fat fibrosis directly.
As medicine has transformed HIV from a fatal diagnosis into a manageable chronic condition, a quieter reckoning has emerged: longevity does not guarantee metabolic safety. Researchers at UC San Francisco have found that people whose HIV is fully suppressed by modern treatment still carry hidden scarring in their fat tissue — scarring that predisposes them to type 2 diabetes regardless of their body weight or the medications they take. The discovery reminds us that what is invisible to the eye, and even to the scale, may still be written in the body's deeper language.
For decades, HIV meant an early death. Modern antiretroviral therapy changed that equation so thoroughly that HIV is now a chronic condition compatible with a long life. But longevity has surfaced a new and poorly understood threat: even people whose virus is completely suppressed face a disproportionately high risk of developing type 2 diabetes.
A UC San Francisco research team set out to understand why. They recruited 46 people with well-controlled HIV and 74 HIV-negative participants, deliberately excluding anyone who was obese or already diabetic. Blood draws and fat biopsies told a striking story: the HIV patients' fat tissue was fibrotic — scarred — and that scarring correlated strongly with insulin resistance, the metabolic precursor to diabetes. Crucially, the scarring appeared regardless of body weight or which HIV medications the patients used, meaning a clinician looking at an apparently healthy patient could easily miss what the tissue was quietly signaling.
The team also identified endotrophin, a blood protein that reflects the degree of fat fibrosis, as a potential early-warning marker. In time, measuring endotrophin could help doctors intervene before diabetes develops in their highest-risk HIV patients.
To probe the mechanism, researchers examined gene activity in the fat samples. Genes governing structural remodeling around fat cells were overactive, immune pathways were inflamed, and the genes that regulate insulin function and fat metabolism were underperforming. This molecular profile differed meaningfully from the fibrosis seen in obese people, suggesting HIV carves its own distinct metabolic path.
The study, published in JCI Insight, carries an important limitation: because each participant was measured only once, the researchers cannot yet confirm that fat fibrosis directly causes insulin resistance rather than both arising from some deeper HIV-related process. Lead author Diana Alba describes the work as a foundation — one that points toward a future where endotrophin testing could help predict the metabolic trajectory of long-term HIV survivors, and where treating the scarring itself might one day prevent diabetes from ever arriving.
For decades, HIV was a death sentence. Now it's a chronic condition you can live with for decades. But living longer with HIV has revealed a new problem: people whose virus is completely controlled by modern drugs still face an unusually high risk of type 2 diabetes. A team at UC San Francisco wanted to understand why.
They gathered 46 people with well-controlled HIV and 74 people without HIV, making sure none of them were obese or already diabetic. Then they drew blood and took fat biopsies from each participant. What they found was striking: the HIV patients' fat tissue was scarred—fibrotic, in medical terms—and this scarring was tightly linked to insulin resistance, the metabolic dysfunction that precedes diabetes. The scarring showed up regardless of how much the patients weighed or which HIV medications they took.
This matters because it means you can look at someone with HIV, see they're at a healthy weight, and still miss a serious metabolic problem brewing underneath. The body's exterior tells one story; the tissue tells another. The researchers also identified a blood marker—a protein called endotrophin—that reflects this hidden scarring. Eventually, this marker could help doctors identify which HIV patients are at highest risk and intervene before diabetes develops.
To understand where the scarring comes from, the team examined gene expression in the fat tissue samples. They found that genes involved in remodeling the structural material around fat cells were working overtime, and immune response pathways were activated. Meanwhile, the genes that normally control how insulin works and how the body processes fats were underactive. This molecular signature was distinctly different from the fat scarring seen in obese people, suggesting HIV creates its own unique metabolic damage.
Suneil Koliwad, who leads the endocrinology division at UCSF Health and oversaw the research, framed the finding as progress. "In a few decades, we've turned HIV from an often-tragic disease into a manageable, chronic condition," he said. "These findings get us closer to preventing the unique and emerging metabolic health problems of this growing population." The study appeared in JCI Insight in late June.
There's an important caveat: because the researchers measured each participant only once, they can't yet prove that fat scarring directly causes insulin resistance and diabetes, or whether both are symptoms of some deeper HIV-related process. But Diana Alba, the study's lead author and an assistant professor of medicine at UCSF, sees the work as a foundation. "We think that fat fibrosis, detectable via endotrophin, could someday give us a lens into predicting the metabolic future of people living with HIV," she said. The next step is figuring out whether treating the scarring itself could prevent diabetes in this population.
Bemerkenswerte Zitate
In a few decades, we've turned HIV from an often-tragic disease into a manageable, chronic condition. These findings get us closer to preventing the unique and emerging metabolic health problems of this growing population.— Suneil Koliwad, Chief of Endocrinology and Metabolism, UCSF Health
We think that fat fibrosis, detectable via endotrophin, could someday give us a lens into predicting the metabolic future of people living with HIV.— Diana Alba, lead author and assistant professor of medicine, UCSF
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical ↗
Health & Medicine